Colombia President Abelardo De La Espriella Pledges Drug Crackdown, Economic Reforms 
ICE to Complete Nationwide Body Camera Rollout by End of August 
Treasury Wine Estates Shares Jump as U.S. Overhaul Lifts FY2026 Outlook 
Ukraine Accuses Russia of Systematic Torture of POWs and Civilian Detainees 
OpenAI Restricts Astra AI Over Cyberattack Risks 
Berkshire Hathaway Cash Falls as Abel Boosts Stock Buybacks 
Iran-Oman Near Strait of Hormuz Deal as Shipping Tensions Persist 
Deutsche Bank Upgrades Persimmon to Buy After Strong First-Half Results 
France Keeps Top Health Alert as Officials Brace for Another Heatwave 
Houthi Attack on Yemen’s Mocha Port Kills Seven, Injures 30 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
North Korea Slams Japan’s 2026 Defense White Paper 
Hims & Hers Shares Fall as GLP-1 Costs Widen Q2 Loss 
NIH Infectious Disease Leadership Shake-Up Raises Concerns Amid Ebola, Hantavirus Outbreaks 
US ‘Digging In’ Across Indo-Pacific, Pentagon Official Says 
Mercedes-Benz Stock Offers Deep-Value Potential as Citi Sees Recovery Catalysts 
FCC Steps Up China Tech Crackdown as Beijing Pushes Back 
Novo Nordisk has named U.S. pharmaceutical executive Greg Miley as its new Global Head of Corporate Affairs, a strategic move as the Danish drugmaker faces heightened scrutiny from U.S. President Donald Trump over drug pricing. Miley, formerly Senior Vice President of Government Affairs at AbbVie, announced his appointment on LinkedIn, with Novo Nordisk confirming the news to Reuters.
The company stated that Miley will officially join in early November, overseeing global communications and public affairs. His extensive experience in the U.S. pharmaceutical sector is expected to help Novo strengthen its political and regulatory strategies in its largest market—the United States. A company source noted that Miley’s top priority will be managing relations with the Trump administration, which has recently intensified pressure on pharmaceutical firms to reduce prices.
Miley’s appointment aligns with new CEO Mike Doustdar’s efforts to regain investor confidence through a broad restructuring initiative aimed at improving competitiveness in the growing obesity drug market, particularly against Eli Lilly. The overhaul involves cutting about 9,000 jobs worldwide, including 5,000 in Denmark and several in the U.S.
In his LinkedIn post, Miley expressed optimism about enhancing Novo’s global communication and public affairs, noting his upcoming relocation to Denmark. Industry insiders say other major pharma companies have also been recruiting public affairs experts with strong Republican ties to navigate Washington’s policy landscape.
Shares of Novo Nordisk and Eli Lilly dropped on Friday following Trump’s statement that the price of Ozempic—Novo’s diabetes drug containing the same ingredient as its popular weight-loss drug Wegovy—would be lowered.
Miley brings nearly two decades of experience in pharmaceutical government relations, with past roles at Abbott and Pfizer, making him a pivotal figure in Novo’s next phase of global engagement.
